3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Multiple Myeloma
7
Recurrence
5
Neoplasms
2
Leukemia, Myeloid, Acute
2
Endometrial Neoplasms
2
Uterine Neoplasms
1
Uterine Diseases
1
Primary Myelofibrosis
1
Neoplasms by Site
1
Myeloproliferative Disorders
1
Lymphoma, Large B-Cell, Diffuse
1
Genital Diseases
1
COVID-19
1
Interventions
pembrolizumab
4
Gemcitabine
4
padeliporfin
3
napabucasin
3
Pemetrexed
3
Paclitaxel
3
Drug Therapy
3
Cisplatin
3
Carboplatin
3
130-nm albumin-bound paclitaxel
3
ribociclib
2
palbociclib
2
Mitomycin
2
Gonadotropin-Releasing Hormone
2
Fluorouracil
2
Bevacizumab
2
Anastrozole
2
Albumin-Bound Paclitaxel
2
AZD9833
2
valrubicin
1
selinexor
1
pralsetinib
1
patritumab
1
palladium-bacteriopheophorbide
1
linifanib
1
ipatasertib
1
enfortumab vedotin
1
camrelizumab
1
atezolizumab
1
abemaciclib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Neoplasms by Site
×
selinexor
×
Clear all
NCT03555422
2026-04-13
ENGOT-EN5
Karyopharm Therapeutics Inc
Phase 3
Completed
263 enrolled